Edivoxetine, formerly known as LY2216684, is is a selective norepinephrine reuptake inhibitor under development for attention-deficit hyperactivity disorder (ADHD) and as an antidepressant treatment. It was in phase III clinical trials, in 2012, for major depressive disorder, but failed to get approval. References: Hoaglund Hyzer CS, Fadda HM, Rodriguez JO, Aburub A. Leveraging BCS in Development: A Case Study. Mol Pharm. 2015 Oct 5;12(10):3685-90. doi: 10.1021/acs.molpharmaceut.5b00450. Epub 2015 Sep 17. PubMed PMID: 26365521.

纯度：≥98%

CAS：1194508-25-2